{"schema_version":"secwatch.filing_event.v1","accession":"0001404644-24-000054","form_type":"8-K","ticker":"NGNE","cik":"0001404644","company_name":"Neurogene Inc.","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.268959+00:00","generated_at":"2026-06-02T03:30:06.348152+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Neurogene Q1 net loss $16.9M; NGN-401 safety positive, on track for efficacy data 4Q24","bullets":["Cash and investments $169.5M as of March 31, 2024; cash runway into 2H 2026.","R&D expenses $13.5M (up 31% YoY); net loss $16.9M vs $12.3M in Q1 2023.","NGN-401 gene therapy for Rett syndrome well-tolerated; all AEs mild/Grade 1.","Australian regulatory clearance received; interim efficacy data from Cohort 1 expected 4Q 2024.","Advancing early-stage pipeline; another product candidate expected to enter clinic in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001404644-24-000054","json":"https://secwatch.observer/filing/0001404644-24-000054.json","markdown":"https://secwatch.observer/filing/0001404644-24-000054.md","text":"https://secwatch.observer/filing/0001404644-24-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000054/0001404644-24-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000054/ngne-20240510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T03:30:06.348152+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"117ff2947230ac2e547e68c314f8ecfd325c38a6","claim":"Neurogene Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 10, 2024, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000054/0001404644-24-000054-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}